Krankenhaus Waldfriede e.V.

Running trials

• Enrolling by invitation

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· Phase 2· Source

• Recruiting

  A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease

  2025-522001-38-00· Phase 2· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· Source

• Recruiting

  A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  NCT07012395· Phase 2· Source

• Recruiting

  A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  NCT06227910· Phase 3· Source

• Recruiting

  Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  NCT06456593· Phase 2· Source

• Recruiting

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· Phase 2· Source

• Active, not recruiting

  Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis

  NCT03843385· Phase 3· Source

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Source

• Active, not recruiting

  An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03950232· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ulcerative colitis5 recruiting
• Crohn's disease4 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  Phase IIa Study Evaluating AZD7798 in Crohn's Disease

  NCT06450197· Phase 2· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Source

• Completed

  A Long-term Safety Study of a Second Treatment with Darvadstrocel for Treating Complex Perianal Fistulas in Adults with Crohn's Disease

  NCT04118088· Phase 4· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

  NCT03105102· Phase 3· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Source